Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 11/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31589264 | 0.89 | PDK4 (0.46) | PDK4GRM5GRM1PDE10ANAMPT | |
| SCHEMBL25571069 | 0.89 | PDK4 (0.54) | PDK4GRM5GRM1PDE10ANAMPT | |
| SCHEMBL31025087 | 0.89 | PDK4 (0.54) | PDK4GRM5GRM1PDE10ANAMPT | |
| SCHEMBL16836230 | 0.85 | PDK4 (0.49) | PDK4GRM5GRM1NAMPTHTR6 | |
| SCHEMBL17001926 | 0.85 | PDK4 (0.59) | PDK4GRM5GRM1PDE10ANAMPT | |
| SCHEMBL31040352 | 0.85 | PDK4 (0.59) | PDK4GRM5GRM1PDE10ANAMPT | |
| SCHEMBL17655532 | 0.84 | PDK4 (0.61) | PDK4GRM5GRM1PDE10ANAMPT | |
| SCHEMBL30676170 | 0.84 | GRM5 (0.61) | PDK4GRM5GRM1PDE10ANAMPT | |
| SCHEMBL15951022 | 0.84 | PDK4 (0.60) | PDK4GRM5GRM1PDE10ANAMPT | |
| SCHEMBL2631187 | 0.84 | GRM5 (0.61) | PDK4GRM5GRM1PDE10ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550252-B1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHIONOGI & CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHIONOGI & CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-8324249-B2 | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324249-B2 | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2011119461-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHINOGI & CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHINOGI & CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| WO-2010014257-A2 | TETRAHYDROPYRIDINYL AND DIHYDROPYRROLYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | HTR1A, HTR1D, HTR5A | PDK4 2972/4885GRM5 309/4885GRM1 157/4885 |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | TRPV1, CACNA1A, CACNA1E | PDK4 2303/4885GRM5 265/4885GRM1 428/4885 |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | TRPV1, CACNA1A, CACNA1E | PDK4 2303/4885GRM5 265/4885GRM1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.